enGene Holdings: Key Catalysts Incoming For 2026 [Seeking Alpha]
enGene Holdings Inc. (ENGN)
Company Research
Source: Seeking Alpha
ENGN's lead candidate, detalimogene voraplasmid, demonstrated a 63% complete response rate at 3 months in NMIBC, with favorable tolerability and pivotal cohort enrollment exceeding targets. ENGN plans a pivotal LEGEND cohort update at a spring 2026 medical conference, with a BLA submission for FDA approval anticipated in the second half of 2026. With $275.9 million in liquidity and a cash runway into 2H 2028, ENGN is well-capitalized for key milestones, though long-term efficacy and regulatory risks remain. timandtim/DigitalVision via Getty Images Topline Summary And Update I've written several times about my optimistic take on enGene Holdings Inc. ( ENGN ), most recently back in November , where I reaffirmed a "Buy" sentiment after a period of significant momentum in This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72
Show less
Read more
Impact Snapshot
Event Time:
ENGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENGN alerts
High impacting enGene Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ENGN
News
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of CarePR Newswire
- enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference [Yahoo! Finance]Yahoo! Finance
- enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update [Yahoo! Finance]Yahoo! Finance
- enGene (ENGN) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ENGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hold".MarketBeat
- enGene (ENGN) had its price target lowered by Oppenheimer Holdings, Inc. from $33.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
ENGN
Sec Filings
- 3/9/26 - Form S-8
- 3/9/26 - Form 424B5
- 3/9/26 - Form 8-K
- ENGN's page on the SEC website